survey
impact
virtual
screen
concept
discuss
field
drug
discoveri
natur
confront
steadili
increas
number
secondari
metabolit
grow
number
molecular
target
relev
therapi
human
disord
huge
amount
inform
need
handl
virtual
screen
filter
experi
alreadi
show
great
promis
deal
larg
librari
potenti
bioactiv
molecul
util
brows
databas
molecul
fit
either
establish
pharmacophor
model
three
dimension
structur
macromolecular
target
howev
discoveri
natur
lead
candid
applic
silico
tool
far
almost
neglect
sever
reason
one
concern
scarc
avail
natur
product
np
databas
contrast
synthet
librari
anoth
reason
problemat
compat
np
modern
robot
high
throughput
screen
ht
technolog
argument
deal
incalcul
avail
pure
natur
compound
often
complex
chemistri
thu
research
field
timeconsum
highli
complex
expens
ineffect
nevertheless
natur
deriv
compound
among
favor
sourc
drug
candid
ration
econom
search
new
lead
structur
natur
must
therefor
prioriti
order
overcom
problem
demonstr
basic
principl
requir
limit
virtual
screen
strategi
support
applic
np
research
alreadi
perform
studi
sensibl
exploit
molecular
divers
secondari
metabolit
howev
ask
virtual
screen
concept
interfac
wellestablish
strategi
classic
pharmacognosi
use
effort
maxim
efficaci
drug
discoveri
integr
virtual
screen
workflow
outlin
shall
help
motiv
np
research
dare
step
toward
power
silico
tool
field
drug
discoveri
confront
paradox
situat
highli
effici
tool
advanc
technolog
molecular
knowhow
eg
area
genom
combinatori
chemistri
high
throughput
screen
ht
robot
miniatur
process
cycl
could
find
entranc
big
pharmaceut
industri
costli
procedur
expect
rais
number
launch
drug
substanc
howev
result
disappoint
adam
smith
chiefeditor
natur
present
sober
data
research
develop
expens
lead
pharma
compani
versu
new
drug
market
steadili
fallen
recent
year
despit
increas
financi
effort
side
face
high
tradit
impact
natur
deriv
medicin
incred
success
stori
natur
product
np
potent
remedi
begin
human
therapeut
activ
modern
research
drug
develop
nevertheless
larg
pharmaceut
compani
scale
termin
work
np
oper
reason
behind
drug
discoveri
process
start
natur
sourc
hardli
compat
today
highli
autom
drug
discoveri
technolog
thu
preemin
combinatori
chemistri
prefer
method
gener
new
drug
lead
led
compar
neglect
valuabl
resourc
william
strohl
merck
research
laboratori
summar
difficulti
np
program
versu
synthet
chemic
editori
remark
drug
discoveri
today
includ
exist
alreadi
found
potent
antimicrob
antitumor
np
lack
suffici
derepl
program
prevent
repeat
discoveri
ii
fact
contrast
highli
sophist
molecular
target
np
extract
gener
regard
dirti
difficult
assay
timeconsum
iii
obtain
assay
hit
result
bioguid
fraction
np
structur
still
elucid
compar
synthet
chemic
iv
np
often
deem
structur
complex
possess
multipl
hydroxyl
moieti
keton
chiral
center
strohl
nevertheless
conclud
list
number
advantag
appli
activ
np
program
final
describ
expens
endeavor
howev
well
worth
cost
use
np
singlemost
success
strategi
discoveri
new
drug
lead
clearli
shown
differ
statist
increas
call
recent
year
research
np
sign
may
play
activ
role
futur
drug
discoveri
process
sinc
reintroduc
may
help
rediscov
sweet
spot
drug
discoveri
date
natur
compound
publish
terrestri
flora
intens
investig
last
decad
potenti
find
new
np
slumber
untap
biota
howev
nearli
inconceiv
estim
approxim
describ
high
plant
speci
ever
focu
phytochem
pharmacolog
investig
sober
percentag
field
bacteri
less
fungal
speci
less
main
part
known
np
belong
secondari
metabolit
compound
provid
live
system
characterist
featur
mandatori
surviv
contain
inher
largescal
structur
divers
chemic
scaffold
publish
np
uniqu
made
chemist
past
year
research
discov
mani
potenti
therapeut
target
sinc
complet
human
genom
gene
least
number
protein
assum
thu
increas
number
macromolecular
target
like
protein
receptor
enzym
ion
channel
might
patholog
concern
humankind
among
protein
continu
attract
signific
attent
pharmaceut
technolog
valuabl
sourc
drugabl
target
protein
provid
critic
link
gene
diseas
thu
key
understand
basic
biolog
process
drug
discoveri
perform
approxim
target
though
number
potenti
target
estim
rang
taken
togeth
assum
larg
number
drug
lead
hit
conserv
inexhaust
pool
np
prescreen
evolut
dig
recogn
respect
drug
lead
challeng
task
industri
academia
medicin
chemist
pharmacognosist
pharmacologist
np
research
affect
wealth
timeconsum
cost
intens
investig
collect
natur
materi
phytochem
analysi
isol
identif
constitu
basic
procedur
biolog
screen
extract
even
arbitrari
test
isol
metabolit
feasibl
often
perform
though
focus
procedur
thu
unpract
expens
np
divers
access
ration
way
holist
versu
molecular
approach
drug
discoveri
natur
last
centuri
even
today
discoveri
bioactiv
np
develop
potenti
drug
candid
mainli
cover
holist
approach
characterist
workflow
procedur
given
figur
start
knowledg
assumpt
biolog
effect
natur
materi
select
adequ
extract
posit
effect
obtain
multicompon
extract
record
attempt
trace
back
activ
principl
intens
phytochem
analyt
investig
fig
instanc
achiev
bioactivityguid
fraction
target
approach
focus
innov
technolog
tool
combin
analyt
biolog
inform
overview
recent
develop
area
success
exampl
thereof
present
potterat
hamburg
soon
constitu
regard
respons
overal
effect
isol
research
focus
molecular
level
includ
structur
elucid
pharmacolog
profil
synthesi
test
seri
deriv
enabl
insight
structureactivityrelationship
pharmacokinet
aspect
final
potenti
drug
lead
becom
drug
candid
intens
toxicolog
studi
verifi
effect
vivo
fig
recent
advanc
lead
identif
natur
work
molecular
base
holist
one
first
prerequisit
bioin
tradit
earli
drug
develop
natur
base
drug
candid
format
compris
structur
gene
protein
bioinformat
substanti
knowledg
molecular
target
function
accur
structur
inform
proteinligand
interact
secondli
essenti
refer
unambigu
character
structur
secondari
metabolit
prefer
inform
biolog
effect
base
avail
structur
well
biolog
knowledg
side
inform
deduc
chemoinformat
bridg
gap
known
ligand
discoveri
new
lead
structur
fig
increas
understand
fundament
principl
proteinligand
interact
steadili
grow
number
potenti
experiment
prove
ligand
provid
undream
possibl
toward
ration
concept
drug
discoveri
howev
much
expect
human
brain
profit
alreadi
publish
inform
thu
effici
effect
approach
benefit
today
knowledg
np
area
medicin
chemistri
comput
method
like
virtual
screen
experi
alreadi
prove
satisfi
requir
need
exploit
avail
structur
inform
understand
specif
molecular
recognit
event
clarifi
function
target
macromolecul
though
ration
procedur
search
bioactiv
natur
product
great
demand
find
needl
haystack
comput
assist
could
hardli
break
natur
product
research
common
idea
comput
approach
within
earli
drug
discoveri
process
mine
less
larg
compound
databas
silico
select
limit
number
candid
propos
desir
biolog
activ
process
term
data
mine
coin
concis
defin
gasteig
coauthor
extract
knowledg
larg
set
data
order
make
predict
new
event
within
lead
discoveri
process
virtual
screen
technolog
larg
enhanc
impact
comput
chemistri
nowaday
chemoinformat
play
predomin
role
earli
phase
drug
research
key
goal
use
method
reduc
overal
cost
associ
discoveri
develop
new
drug
identifi
promis
candid
focu
experiment
effort
recent
publish
book
review
impact
comput
chemistri
lead
structur
determin
highlight
effort
structur
biolog
target
known
high
throughput
dock
turn
valuabl
structurebas
virtual
screen
method
use
within
context
score
hit
retriev
still
remain
question
often
discuss
fact
current
major
weak
dock
program
lie
dock
algorithm
still
inaccuraci
function
use
estim
affin
ligand
target
socal
score
function
previous
stahl
rarey
analyz
score
function
virtual
screen
give
valuabl
insight
strength
weak
current
use
model
affin
estim
combin
sever
differ
score
function
term
consensu
score
turn
one
possibl
answer
question
rais
previous
fact
sever
author
recent
describ
effort
area
exampl
given
refer
theoret
studi
author
demonstr
consensu
score
outperform
singl
score
simpl
statist
reason
moder
number
score
function
ie
three
four
suffici
purpos
consensu
score
howev
shown
consensu
score
alon
suitabl
case
dock
highlight
recent
review
krovat
coauthor
consider
effort
still
devot
optim
score
function
restrict
free
access
np
librari
see
number
virtual
screen
studi
publish
ration
access
bioactiv
np
limit
exampl
use
high
throughput
dock
structurebas
virtual
screen
tool
given
liu
zhou
appli
theoret
approach
find
natur
ligand
potenti
inhibitor
sarscov
proteas
viru
target
sever
acut
respiratori
syndrom
use
dockingbas
virtual
screen
cycl
appli
druglik
filter
final
propos
drug
candid
two
databas
compris
metabolit
marin
organ
compound
tradit
chines
medicin
viru
organ
main
interest
studi
perform
toney
et
al
focus
main
proteinas
crystal
structur
attract
target
use
start
point
virtual
dock
screen
nci
databas
search
nonpeptidyl
inhibitor
author
identifi
natur
occur
terpenoid
alkaloid
sabadinin
ie
cevin
potenti
antisar
agent
author
group
around
stefano
moro
could
identifi
ellag
acid
inhibitor
protein
kinas
screen
inhous
gener
databas
almost
structur
natur
compound
combin
four
dock
protocol
five
score
function
util
dock
rank
molecul
databas
consensu
dock
suggest
ellag
acid
one
promis
candid
assumpt
could
verifi
experiment
studi
reveal
np
highli
potent
inhibitor
k
nm
estrogen
receptorplay
key
role
regul
brain
develop
estrogeninduc
promot
neurogenesi
memori
use
coordin
cocryst
structur
human
estrogen
receptorbound
genistein
start
point
zhao
brinton
pursu
receptorbas
molecular
dock
approach
focus
search
natur
estrogen
receptor
select
ligand
twelv
candid
molecul
suggest
databas
screen
select
author
determin
bind
affin
select
three
compound
belong
flavanoid
famili
display
bind
select
estrogen
receptorov
similar
approach
employ
liu
coauthor
appli
dock
virtual
screen
filter
experi
author
discov
potent
inhibitor
potassium
ion
channel
chines
np
databas
pharmacophor
concept
proven
extrem
success
ration
structureact
relationship
also
larg
impact
develop
appropri
effici
virtual
screen
profil
combinatori
librari
compound
classif
oftenus
applic
concept
although
well
establish
combinatori
chemistri
point
tool
describ
section
likewis
consider
impact
ration
find
new
potenti
lead
compound
origin
immens
sourc
secondari
metabolit
prior
use
pharmacophor
model
biolog
screen
np
effici
procedur
sinc
quickli
elimin
molecul
possess
requir
featur
thu
lead
dramat
increas
enrich
compar
pure
random
screen
experi
previou
studi
conduct
doman
coauthor
molecul
reveal
protein
tyrosin
inhibitor
ic
ht
approxim
compound
hand
molecul
suggest
molecular
dock
found
activ
thu
dockingbas
virtual
screen
enrich
hit
rate
almost
random
screen
one
forget
howev
addit
molecular
characterist
reflect
pharmacophor
model
physicochem
properti
relev
adm
toxicolog
properti
must
taken
account
decid
upon
compound
develop
rapid
identif
elimin
compound
unsuit
physicochem
pharmacokinet
properti
pivot
step
earli
drug
discoveri
process
evalu
tradit
high
throughput
screen
discuss
detail
avdeef
testa
must
consid
synthet
well
np
though
studi
reveal
secondari
metabolit
high
scaffold
divers
biosynthes
molecul
also
show
structur
spatial
characterist
closer
drug
lead
synthet
molecul
typic
np
includ
chiral
center
stereochem
architectur
much
complex
synthet
molecul
furthermor
usual
contain
carbon
hydrogen
oxygen
howev
less
nitrogen
atom
compar
synthet
surprisingli
np
often
show
molecular
weight
higher
da
combin
high
polar
clear
contrast
lipinski
rule
five
nevertheless
np
contain
two
violat
lipinski
rule
summari
natur
chemistri
seen
highli
divers
scaffold
endow
potenti
drugabl
pharmacophor
structurebas
pharmacophor
model
inevit
prerequisit
gener
structurebas
model
knowledg
ligandtarget
interact
includ
avail
structur
target
either
xray
crystallographi
nmr
construct
basi
structur
homolog
protein
uniqu
platform
contain
coordin
experiment
solv
protein
structur
brookhaven
protein
data
bank
pdb
crystallin
complex
ligand
bound
protein
activ
site
best
requir
start
construct
structurebas
model
case
one
may
profit
exact
inform
ligand
bioactiv
conform
preserv
bind
site
crystallin
complex
build
structurebas
pharmacophor
depict
step
step
way
figur
new
softwar
tool
recent
describ
success
gener
chemic
featuresbas
model
softwar
ligandscout
program
ligand
interpret
data
mine
pdb
perform
program
allow
detect
relev
interact
point
ligand
protein
bind
mode
ligand
activ
site
protein
visual
sophist
way
ligandscout
algorithm
perform
stepwis
interpret
ligand
molecul
planar
ring
detect
assign
function
group
pattern
determin
hybrid
state
final
assign
pattern
interpret
ligand
molecul
basi
next
step
autom
gener
pharmacophor
model
deriv
data
provid
crystallin
complex
pdb
automat
detect
classif
proteinligand
interact
hydrogen
bond
charg
transfer
lipophil
region
lead
collect
chemic
featur
pharmacophor
model
graphic
userinterfac
provid
integr
view
protein
ligand
pharmacophor
model
interact
line
previous
publish
studi
ligandscout
use
detect
interpret
crucial
interact
pattern
ligand
factor
xa
protein
structur
second
step
program
catalyst
state
art
virtual
screen
platform
use
rapid
virtual
screen
multiconform
structur
databas
inform
pharmacophor
pattern
ie
coordin
interact
point
obtain
interpret
ligandscout
pharmacophor
definit
result
specif
interact
model
abl
map
ligand
bioactiv
conform
retriev
select
fraction
known
factor
xa
inhibitor
within
small
subset
larg
derwent
world
drug
index
librari
applic
ligandscout
pharmacophor
definit
cover
ration
search
angiotensin
convert
enzym
ace
inhibitor
virtual
screen
approxim
million
compound
variou
commerci
databas
hit
reduct
select
achiev
use
five
featur
hypothesi
base
recent
resolv
inhibitorbound
crystal
structur
seventeen
virtual
hit
select
experiment
valid
bioassay
concept
confirm
sinc
reveal
inhibitor
barreca
coauthor
develop
structurebas
pharmacophor
model
ligandscout
discoveri
new
scaffold
act
nonnucleosid
revers
transcriptas
inhibitor
virtual
screen
larg
chemic
databas
six
virtual
hit
final
select
determin
inhibitori
effect
belong
new
scaffold
class
one
famili
exhibit
revers
transcriptas
inhibitori
activ
submicromolar
concentr
recent
publish
work
schuster
et
al
present
socal
cytochrom
profil
sever
structurebas
gener
ligandscout
ligandbas
pharmacophor
model
use
catalyst
substrat
inhibitor
five
cytochrom
isoenzym
creat
valid
author
group
result
show
model
suitabl
fast
pharmacokinet
profil
larg
druglik
databas
context
parallel
screen
particular
interest
wherea
usual
virtual
screen
cycl
interact
thousand
even
million
databas
entri
brows
one
pharmacophor
model
contrari
case
parallel
screen
lowenerget
conform
one
structur
screen
potenti
interact
numer
model
basic
parallel
screen
recent
present
steindl
coauthor
furthermor
author
exemplifi
strategi
activ
profil
use
set
hiv
proteas
pharmacophor
model
silico
concept
particular
interest
virtual
scrutin
drug
candid
preliminari
activ
profil
relev
put
side
effect
toxic
accord
obtain
interact
virtual
screen
antitarget
eg
herg
cytochrom
p
first
insight
potenti
riski
affin
provid
time
cost
intens
toxicolog
studi
perform
virtual
screen
approach
use
structurebas
pharmacophor
model
reveal
first
applic
exampl
np
research
nikolovskacoleska
coauthor
success
pursu
silico
strategi
area
xlink
inhibitor
apoptosi
xiap
high
resolut
structur
xiap
domain
complex
ntermin
end
smacdiablo
protein
endogen
ligand
respect
xiap
bind
pocket
use
start
point
virtual
screen
inhous
databas
embelin
japanes
ardisia
herb
emerg
virtual
small
molecul
weight
hit
found
fairli
potent
inhibitor
xiap
use
fluoresc
polar
bind
assay
group
previous
focus
acetylcholinesteras
ach
accord
cholinerg
hypothesi
pathogenesi
alzheim
diseas
inhibitor
ach
success
use
therapeut
strategi
base
cocryst
structur
ach
ligand
galanthamin
structurebas
pharmacophor
model
gener
use
silico
screen
multiconform
databas
consist
np
obtain
hit
list
promis
virtual
activ
candid
select
name
scopoletin
glucosid
scopolin
ach
inhibitori
effect
first
verifi
crude
extract
scopolia
carniolica
root
use
bioautograph
tlc
assay
isol
coumarin
show
signific
dosedepend
inhibit
ach
micropl
enzym
assay
well
vivo
test
icv
applic
coumarin
rat
result
longlast
pronounc
case
glucosid
even
twofold
higher
increas
neurotransmitt
concentr
one
caus
posit
control
galanthamin
ligandbas
pharmacophor
model
often
howev
lead
discoveri
project
reach
welladvanc
stage
detail
structur
data
protein
target
becom
avail
even
though
well
recogn
modern
method
molecular
biolog
togeth
biophys
comput
approach
enhanc
likelihood
success
obtain
detail
atom
structur
inform
possibl
consequ
often
scientist
identifi
develop
novel
compound
target
use
preliminari
structureact
inform
togeth
theoret
model
interact
respons
consist
work
hypothes
contribut
evolut
use
model
within
framework
chemic
featurebas
pharmacophor
approach
proven
success
allow
percept
understand
key
interact
receptor
ligand
gener
level
functionbas
pharmacophor
repres
common
ensembl
steric
electrostat
featur
differ
compound
necessari
interact
specif
biolog
target
structur
fig
pharmacophor
model
togeth
larg
structur
databas
origin
either
inhous
compound
collect
commerci
vendor
natur
product
databas
proven
extrem
use
silico
screen
experi
use
ligandbas
pharmacophor
model
screen
filter
instead
protein
structur
affin
estim
base
geometr
fit
compound
atom
group
featur
model
case
valu
calcul
often
far
away
realiti
howev
still
use
filter
possibl
hit
nonbind
molecul
addit
pharmacophor
fit
procedur
calcul
demand
consider
lower
dock
algorithm
allow
number
compound
process
time
far
higher
even
high
throughput
dock
sinc
studi
experiment
inform
either
biolog
conform
ligand
target
protein
current
avail
ligandbas
chemic
featur
pharmacophor
approach
provid
essenti
inform
medicin
chemist
sever
success
applic
within
subject
perform
use
catalyst
program
one
lead
softwar
packag
chemic
featurebas
pharmacophor
model
schuster
cowork
succeed
identif
hydroxysteroid
dehydrogenas
type
inhibitor
appli
common
featurebas
pharmacophor
model
virtual
screen
filter
experi
similarli
author
preced
suggest
compound
propos
inhibit
cytochrom
isoenzym
sever
review
cover
success
applic
featurebas
method
publish
kurogi
et
al
krovat
et
al
et
al
outlin
theoret
background
describ
sever
signific
studi
includ
databas
search
strategi
field
np
limit
number
studi
report
ration
access
bioactiv
compound
via
ligandbas
virtual
screen
exampl
method
pursu
discoveri
inhibitor
signalosom
cn
associ
kinas
pkd
use
np
curcumin
emodin
lead
structur
virtual
screen
inhous
databas
carri
among
virtual
hit
seven
np
eg
anthraquinon
piceatannol
found
significantli
induc
apoptosi
inhibit
csnassoci
kinas
use
vitro
cell
cultur
experi
studi
demonstr
power
ligandbas
approach
appli
pharmacophor
model
ligand
therein
reliabl
pharmacophor
model
could
extract
sole
ligand
structur
inform
compound
potent
affin
receptor
known
literatur
structur
align
deriv
distinct
common
featur
arrang
combin
spatial
restrict
use
gener
pharmacophor
model
abl
retriev
compound
high
affin
valu
among
also
np
like
solanidin
ligandbas
approach
use
variou
form
discrimin
analysi
eg
artifici
neural
network
simul
base
collect
mathemat
model
interconnect
organ
differ
layer
analog
adapt
human
learn
process
usual
train
learn
set
appli
one
molecular
descriptor
order
form
cluster
enabl
distinguish
differ
object
properti
result
model
appli
make
predict
test
set
valid
model
may
use
deriv
qsar
chemic
relat
structur
mine
larger
dataset
one
may
distinguish
supervis
unsupervis
eg
kohonen
network
learn
method
discuss
detail
zupan
gasteig
success
applic
exampl
within
field
np
publish
wagner
et
al
author
use
dataset
structur
divers
sesquiterpen
lacton
known
nfb
inhibitori
activ
deriv
qsar
applic
multipl
structur
represent
descriptor
singl
model
achiev
provid
detail
inform
structur
influenc
investig
biolog
activ
sangma
coauthor
pursu
combin
two
approach
predict
new
inhibitor
rt
pr
np
databas
compris
metabolit
thai
medicin
plant
high
throughput
dock
molecul
target
enzym
selforgan
map
gener
reduc
number
promis
candid
test
set
differ
silico
methodolog
previous
appli
cherkasov
coauthor
aid
discoveri
natur
nonsteroid
ligand
human
sex
hormon
bind
globulin
therein
rigor
crossvalid
neural
network
base
qsar
model
identifi
prospect
compound
structur
collect
commerci
natur
substanc
stringent
qsar
rank
combin
dock
studi
pharmacophoreaid
databas
search
integr
comput
method
result
convinc
predict
tool
identifi
set
structur
divers
np
everi
fourth
compound
abl
inhibit
target
protein
micromolar
rang
compound
arbitrari
structur
divers
known
activ
target
particularli
suitabl
gener
ligandbas
pharmacophor
model
describ
also
structur
similar
studi
use
decis
tree
object
find
good
distinct
possibl
basi
set
molecular
descriptor
identifi
molecular
featur
share
differ
subset
activ
compound
accordingli
filter
compound
within
dataset
combin
lack
use
simpl
logic
descript
one
model
ensembl
decis
tree
tend
prefer
option
sinc
consensu
vote
among
tree
give
approach
higher
predict
accuraci
one
form
multipl
decis
tree
well
perform
virtual
screen
larg
databas
random
forest
chemoinformat
method
recent
appli
theoret
work
perform
ehrman
cowork
predict
ligand
multipl
target
like
cyclooxygenas
cox
lipoxygenas
lox
aldos
reductas
enzym
etc
larg
dataset
chines
herb
advent
structur
databas
provid
basi
develop
feasibl
automat
method
search
new
lead
structur
conceptu
virtual
screen
concept
present
origin
synthet
chemistri
applic
howev
well
adapt
np
chemistri
prior
silico
filter
experi
structur
databas
requir
effici
gener
reason
energet
minim
conform
assum
meet
approxim
conform
might
biolog
relev
underli
algorithm
structur
gener
conform
analysi
implement
commerci
softwar
tool
eg
corina
catalyst
program
catalyst
avail
accelri
inc
san
diego
ca
usa
wwwaccelryscom
field
np
virtual
screen
applic
mainli
restrict
due
lack
searchabl
resourc
structur
well
defin
natur
compound
gener
molecular
databas
free
access
internet
may
compris
high
number
molecul
eg
chembank
http
chembankbroadharvardedu
pubchem
http
pubchemncbinlmnihgov
howev
inform
number
contain
natur
molecul
rare
avail
librari
nation
cancer
institut
nci
store
structur
inform
half
million
compound
synthet
natur
origin
collect
test
nci
sinc
half
synthet
compound
repres
larg
major
sampl
may
use
free
thu
public
domain
call
open
nci
databas
develop
therapeut
program
ncinih
http
dtpnci
nihgovwebdatahtml
interest
properti
predict
approach
compound
contain
open
databas
provid
poroikov
coauthor
use
program
pass
predict
activ
spectra
substanc
silico
tool
complex
search
differ
type
activ
provid
eg
case
antineoplast
effect
author
could
demonstr
substanti
dataset
enrich
random
select
use
passpredict
probabl
librari
cover
major
part
entiti
natur
least
thousand
consist
structur
inform
exclus
natur
origin
free
charg
eg
tradit
chines
medicin
databas
tcmd
http
dictionari
natur
product
databas
launch
chapman
hall
dnp
http
wwwchemnetbasecom
provid
chemic
physic
data
natur
compound
gather
world
chemic
literatur
excel
survey
public
commerci
databas
focus
np
recent
publish
coauthor
author
provid
inform
store
characterist
databas
webaddress
total
number
compound
given
number
natur
one
addit
select
supplier
manufactur
natur
compound
extract
given
new
databas
introduc
author
super
natur
databas
store
inform
avail
np
thu
allow
select
compound
purchas
moreov
number
noncommerci
inhous
creat
databas
use
differ
group
virtual
screen
studi
np
eg
marin
natur
product
databas
mndp
natur
product
databas
npd
databas
base
antiqu
sourc
de
materia
medica
pedaniu
dioscurid
dio
databas
fed
metabolit
ethnopharmacolog
known
plant
recent
ehrman
coauthor
gener
multiconform
databas
chines
herbal
constitu
contain
total
compound
chines
herb
integr
strategi
discoveri
bioactiv
np
less
accur
predict
potenti
activ
compound
virtual
screen
doubtlessli
ration
earli
drug
discoveri
process
filter
experi
definit
assist
save
costli
timeintens
pharmacolog
assay
sinc
pool
predict
ligand
ie
virtual
hit
usual
drastic
reduc
compar
initi
amount
compound
ie
demand
made
good
model
select
targetspecif
one
hand
also
semin
lose
mani
valuabl
ligand
filter
process
far
demand
fulfil
strongli
depend
qualiti
inform
use
basi
gener
model
algorithm
underli
virtual
screen
process
medicin
chemistri
activ
predict
usual
regard
satisfi
enrich
np
research
howev
percentag
may
scarc
rare
found
larg
set
natur
compound
acquir
easili
minor
secondari
metabolit
commerci
avail
usual
incred
high
price
thu
extraordinari
charg
effort
typic
necessari
virtual
hit
natur
avail
pharmacolog
test
process
embrac
acquisit
natur
materi
describ
contain
desir
metabolit
point
phytochem
analysi
isol
though
advanc
separ
techniqu
analyt
instrument
innov
tool
structur
identif
phytochemist
dispos
remain
complex
sometim
uncertain
endeavor
result
obtain
silico
predict
may
nevertheless
vagu
np
research
method
ask
increas
probabl
follow
straight
tip
possibl
hyphen
sundri
comput
approach
eg
pharmacophorebas
virtual
screen
combin
dock
result
virtual
hit
consid
consensu
hit
appli
two
screen
concept
nevertheless
strategi
remain
virtual
specul
combin
two
approach
complet
diverg
natur
like
comput
empir
one
may
howev
offer
deepen
access
bioactiv
np
may
sometim
help
avoid
distort
view
thu
computeraid
molecular
select
best
combin
discoveri
method
label
integr
approach
increas
probabl
find
real
hit
tradit
pharmacognosi
well
establish
method
target
aim
start
holist
level
includ
hint
ethnopharmacolog
ii
phenomenolog
effect
regist
applic
natur
deriv
prepar
iii
guidanc
chemotaxonomi
iv
phylogenet
select
criteria
v
simpli
inform
gather
highmedium
throughput
screen
extract
recent
publish
review
group
differ
strategi
field
np
present
special
emphasi
antiinflammatori
np
interact
within
arachidon
cascad
integr
comput
strategi
discoveri
natur
bioactiv
compound
introduc
elsewher
concentr
scope
strength
limit
strategi
exampl
literatur
combin
virtual
screen
approach
classic
method
activ
exploit
outlin
soon
sensit
datamin
tool
develop
prove
less
select
find
activ
compound
within
test
set
appli
screen
multiconform
databas
subsequ
procedur
consist
evalu
virtual
hit
consid
physicochem
properti
toxic
pharmacokinet
stage
addit
virtual
filter
tool
profil
adm
paramet
might
invalu
impact
aid
refin
select
compound
sensibl
choic
natur
materi
known
contain
focus
metabolit
worth
investig
detail
crucial
step
requir
comprehens
studi
literatur
consid
hit
content
natur
sourc
avail
mayb
hint
ethnopharmacolog
natur
materi
select
advis
perform
preliminari
assay
crude
extract
fraction
assum
contain
promis
metabolit
though
awar
case
small
hit
amount
present
natur
materi
activ
may
overseen
therefor
advis
first
identifi
promis
constitu
possibl
enrich
extract
test
sampl
score
well
subject
phytochem
investig
way
tricki
select
natur
materi
turn
bold
ventur
ration
endeavor
soon
promis
ie
activ
start
materi
found
principl
two
possibl
strategi
embark
first
one
reli
silico
approach
focus
directli
strategi
discoveri
bioactiv
np
use
integr
virtual
screen
approach
identif
initi
obtain
virtual
hit
within
natur
matrix
appli
analyt
tool
like
lcm
lcnmr
gcm
etc
straightforward
manner
hit
isol
use
differ
chromatograph
separ
step
structur
confirm
compound
test
hope
verifi
predict
activ
strategi
goalori
sinc
pharmacolog
assay
final
isol
virtual
hit
necessari
side
one
may
run
risk
ignor
activ
np
necessarili
fit
pharmacophor
model
second
strategi
focus
bioactivityguid
fraction
irrespect
virtual
hit
use
select
start
materi
follow
concept
final
isol
activ
ingredi
correspond
predict
virtual
hit
approach
usual
associ
higher
phytochem
effort
cost
requir
iter
test
aris
fraction
subfract
evalu
bioactiv
constitu
detail
discoveri
possibl
unknown
metabolit
procedur
howev
indispens
decis
present
way
appropri
investig
hand
strongli
depend
reliabl
select
use
pharmacophor
model
costli
use
assay
strategi
schemat
figur
recent
appli
medicin
plant
antiinflammatori
potenti
known
ethnopharmacolog
sourc
pharmacophor
base
virtual
screen
filter
experi
number
secondari
metabolit
known
mulberri
tree
compli
model
requir
thu
reveal
virtual
hit
inde
vitro
test
attest
extract
moru
root
bark
distinct
cox
inhibitori
potenti
object
find
activ
principl
plant
materi
appli
differ
method
discoveri
first
computeraid
approach
use
identifi
virtual
activ
compound
abl
interact
pharmacophor
model
second
bioactivityguid
fraction
conduct
isol
coxinhibit
constitu
result
isol
nine
compound
belong
chemic
class
sanggenon
moracin
enzym
assay
isol
show
moder
potent
inhibitori
effect
compar
hit
virtual
screen
experiment
data
good
correl
predict
provid
comput
assist
method
vitro
data
could
obtain
case
isol
sanggenon
eg
sanggenon
c
howev
agreement
could
achiev
moracin
eg
moracin
case
virtual
screen
particularli
help
decis
regard
plant
materi
worth
extens
studi
furthermor
disclos
interact
sanggenon
pharmacophor
model
mime
bind
site
target
provid
us
essenti
inform
molecular
requir
coxligand
differ
integr
procedur
schemat
figur
appli
approach
preselect
natur
materi
guid
virtual
predict
number
extract
roughli
screen
bioassay
identifi
activ
one
similar
strategi
collect
inform
tradit
applic
natur
prepar
field
focus
pharmacolog
target
databas
gener
consist
metabolit
known
literatur
includ
extract
came
well
likewis
ethnopharmacolog
knowledg
use
prepar
natur
may
guid
select
np
result
bias
databas
virtual
screen
establish
pharmacophor
model
aim
target
impact
ethnopharmacolog
analyz
previou
studi
group
investig
statist
evid
consid
hint
folk
medicin
discoveri
antiinflammatori
np
util
pharmacophorebas
virtual
screen
techniqu
use
preferenti
target
sinc
key
enzym
inflamm
process
dioscorid
de
materia
medica
written
centuri
ad
use
ethnopharmacolog
sourc
secondari
metabolit
medicin
plant
dioscorid
describ
activ
fever
rheumat
pain
pu
store
multiconform
databas
virtual
screen
valid
pharmacophor
model
result
hit
list
analyz
compar
obtain
screen
unbias
databas
natur
well
synthet
origin
effect
ethnopharmacolog
approach
could
statist
demonstr
obtain
significantli
higher
hit
rate
compar
hit
rate
unbias
natur
well
synthet
databas
follow
strategi
put
hit
may
identifi
modern
analyt
tool
like
lcm
lcnmr
isol
natur
matrix
targetori
way
pharmacolog
test
approach
especi
help
intric
pharmacolog
assay
would
turn
bioguid
fraction
unrealist
endeavor
combin
ethnopharmacolog
base
preselect
plant
materi
comput
approach
report
bernard
cowork
use
strategi
ration
phytochem
lead
discoveri
start
vitro
screen
phospholipas
perform
tradit
use
antiinflammatori
plant
extract
focus
structur
databas
gener
virtual
screen
establish
ligandbas
pharmacophor
model
human
nonpancreat
phospholipas
combin
experiment
data
databas
exploit
molecular
model
result
effici
identif
betulin
betulin
acid
extract
ingredi
distinct
antiinflammatori
vitro
effect
combin
two
differ
complementari
strategi
consist
vitro
screen
silico
assess
recent
describ
van
de
waterbeemd
label
method
combo
approach
use
straight
forward
access
variou
adm
properti
applic
combo
approach
discoveri
np
recent
test
group
search
natur
acetylcholinesteras
inhibitor
mediums
throughput
screen
plant
extract
investig
use
acetylcholinesteras
enzym
test
sampl
show
best
inhibitori
activ
known
secondari
metabolit
fed
small
multiconform
databas
subsequ
subject
virtual
screen
gener
pharmacophor
model
efficaci
procedur
could
confirm
isol
obtain
virtual
hit
ie
lactucopicrin
show
signific
dosedepend
inhibitori
effect
enzym
assay
method
expect
integr
virtual
screen
concept
previous
discuss
detail
j
bajorath
author
final
statement
meaning
integr
virtual
experiment
screen
program
togeth
lesson
learn
structur
genom
hold
great
promis
rapid
consist
identif
high
qualiti
hit
lead
across
diver
class
therapeut
target
though
conclus
particularli
coin
np
come
especi
true
rich
world
secondari
metabolit
hybrid
comput
strategi
quit
sensibl
get
improv
understand
ligandtarget
interact
follow
two
exampl
dock
protocol
help
enlighten
molecular
mechan
bioactiv
natur
compound
chimenti
coauthor
isol
quercetin
among
secondari
metabolit
mediterranean
shrub
hypericum
hircinum
identifi
flavonol
select
inhibitor
maoa
activ
nanomolar
rang
ic
nm
comprehens
understand
underli
molecular
select
conform
analysi
dock
simul
perform
use
recent
crystallograph
structur
human
isoform
maoa
maob
enabl
author
identifi
import
interact
residu
cofactor
within
enzymat
cleft
estim
free
energi
complex
agreement
experiment
data
confirm
distinct
prefer
maoa
cleft
intermolecular
hydrogen
bond
interact
goal
recent
inhous
studi
ration
bind
interact
protoalkaloid
taspin
within
acetylcholinesteras
taspin
isol
bioactivityguid
manner
magnolia
x
soulangiana
reveal
select
inhibitor
acetylcholinesteras
significantli
higher
effect
posit
control
galanthamin
ic
extens
molecular
dock
studi
perform
human
torpedo
californicaacetylcholinesteras
employ
gold
softwar
ver
wwwccdccamacukproductslifesciencesgold
result
suggest
taspin
bind
altern
bind
orient
galanthamin
locat
close
vicin
catalyt
amino
acid
triad
taspin
found
mainli
stabil
sandwichlik
stack
interact
aromat
gorg
enzym
case
studi
activ
natur
compound
alreadi
identifi
thu
silico
tool
employ
data
mine
elicit
put
bind
mode
macromolecular
target
dock
simul
turn
excel
tool
get
idea
assum
molecular
ligand
target
interact
anoth
approach
capit
exactli
justment
observ
comput
predict
may
reveal
idea
interact
specif
target
bind
site
thu
possibl
start
one
compound
unknown
activ
mine
number
structur
disclos
target
term
elabor
pharmacophor
model
fig
ie
parallel
silico
screen
see
previou
soon
orphan
molecul
abl
compli
requir
restrict
impos
model
assess
ration
hint
consequ
focus
compound
subject
pharmacolog
test
predict
target
way
parallel
screen
help
estim
interact
drug
candid
divers
antitarget
canvass
interact
relat
target
perform
activ
profil
approach
parallel
screen
comput
tool
target
fish
get
ration
idea
potenti
target
interact
priorit
target
experiment
evalu
appli
simpl
ligandbas
targetbas
queri
potenti
virtual
screen
target
librari
recent
discuss
didier
rognan
group
structurebas
method
target
screen
pursu
appli
invers
dock
author
use
structur
welldefin
pdb
entri
build
protein
librari
virtual
screen
protein
librari
four
unrel
ligand
suitabl
recov
true
target
specif
ligand
may
well
use
virtual
select
profil
ligand
interest
nettl
coauthor
perform
target
fish
approach
use
ligandbas
procedur
potenti
chemic
descriptor
compar
tool
predict
biolog
target
ligand
probe
basi
similar
refer
molecul
chemic
databas
compris
biolog
annot
compound
ligandbas
tool
fepop
featur
point
pharmacophor
provid
pharmacophor
align
small
molecul
chemic
featur
consist
seen
experiment
ligandreceptor
complex
use
scaffold
jump
within
screen
databas
use
atp
author
abl
identifi
natur
compound
balanol
ligand
highest
effort
appli
strategi
avail
repres
amount
reliabl
pharmacophor
model
cover
wide
rang
relev
target
fig
thu
may
particular
interest
focu
one
patholog
syndrom
eg
obes
inflamm
apoptosi
etc
phenomenolog
activ
np
alreadi
evid
appli
approach
disposit
pharmacophor
model
target
involv
respect
patholog
complex
easier
manag
way
goalori
strategi
may
help
bridg
gap
phenomenolog
effect
underli
molecular
mode
action
pertain
drug
discoveri
natur
face
two
fact
statist
show
myriad
structur
divers
natur
compound
favor
sourc
new
drug
clinic
use
ii
drug
discoveri
process
move
toward
ration
concept
base
increas
understand
molecular
principl
proteinligand
interact
spur
econom
interest
fundament
advanc
made
research
appli
data
mine
strategi
like
virtual
screen
though
awar
potenti
combin
benefit
could
rudimentari
savor
limit
attempt
appli
innov
silico
tool
np
research
pursu
far
search
bioactiv
compound
complex
multidisciplinari
challeng
thu
sensibl
adapt
comput
strategi
demand
profit
econom
way
uniqu
chemic
biolog
divers
associ
np
virtual
screen
techniqu
howev
must
use
exclus
activitypredict
tool
sinc
result
provid
mere
indic
put
activ
creation
interfac
comput
tool
wellestablish
method
pharmacognosi
reason
standard
success
achiev
search
effect
strategi
best
perform
drug
discoveri
process
involv
exploit
inform
gather
bioactivityguid
fraction
onlin
analyt
activ
profil
ethnopharmacolog
screen
chemoinformat
virtual
vitro
screen
studi
first
instanc
behov
modern
pharmacognosi
skill
exploit
knowledg
field
paramount
import
sift
enorm
wealth
np
exampl
underlin
impact
virtual
screen
identif
activ
np
present
survey
though
full
potenti
field
far
untap
earli
result
indic
integr
virtual
screen
approach
targetori
trendset
strategi
howev
computerbas
techniqu
success
use
virtual
screen
entir
depend
way
util
qualiti
underli
experiment
data
advantag
implement
virtual
screen
cycl
compar
convent
vitro
screen
obviou
higher
capac
ii
need
isol
compound
iii
less
experiment
effort
test
iv
theoret
interact
known
np
structur
defin
target
calcul
predict
v
qualiti
hit
compound
increas
addit
druglik
filter
virtual
restrict
adm
properti
thu
diminish
failur
earli
drug
develop
nevertheless
experiment
investig
semin
focus
effect
fashion
cautiou
handl
virtual
hit
togeth
lesson
learn
tradit
pharmacognosi
seem
crucial
success
exploit
treasur
natur
area
virtual
screen
like
play
essenti
role
acceler
earli
stage
drug
discoveri
effici
dig
lead
compound
natur
